Clinically Insignificant Negative Interferences of Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone in New Dimension Vista LOCI Digoxin Immunoassay-Reference-Cited by-同舟云学术

Clinically Insignificant Negative Interferences of Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone in New Dimension Vista LOCI Digoxin Immunoassay

Published:2012-05 Issue:3 Volume:26 Page:143-147
ISSN:0887-8013
Container-title:Journal of Clinical Laboratory Analysis
language:en
Short-container-title:J. Clin. Lab. Anal.

Author:

Dasgupta Amitava¹,Johnson Myrtle J.²,Sengupta Tamal K.³

Affiliation:

1. Department of Pathology and Laboratory Medicine; University of Texas-Houston Medical School; Houston; TX

2. Laboratory Services; Memorial-Hermann Hospital at Texas Medical Center; Houston; TX

3. Department of Surgery; N.R.S Medical College and Hospital; Kolkata; India

Publisher

Wiley

Subject

Microbiology (medical),Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcla.21501/fullpdf

Reference17 articles.

1. Lower serum digoxin concentrations in heart failure and reassessment of laboratory report forms;Sameri;Am J Med Sci,2002

2. Therapeutic drug monitoring of digoxin: Impact of endogenous and exogenous digoxin-like immunoreactive substances;Dasgupta;Toxicol Rev,2006

3. Difference in metabolic profile of potassium canrenoate and spironolactone in rat: Mutagenic metabolites unique to potassium canrenoate;Cook;Arch Toxicol,1988

4. Pharmacokinetics of spironolactone and potassium canrenoate in humans;Kojima;J Pharmacobiodyn,1985

5. The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay;Morris;Eur J Clin Pharmacol,1988

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significant Improvement in Digoxin Immunoassays Over Four Decades: Newer Assays are Less Affected by Interferences;Therapeutic Drug Monitoring;2023-02

2. Digoxin: Pharmacology and toxicology—A review;Environmental Toxicology and Pharmacology;2020-10

3. Therapeutic drug monitoring of cardioactive drugs;Therapeutic Drug Monitoring Data;2020

4. Issues of Interferences in Therapeutic Drug Monitoring;Biotin and Other Interferences in Immunoassays;2019

5. Immunoassays and Issues With Interference in Therapeutic Drug Monitoring;2016